keyword
MENU ▼
Read by QxMD icon Read
search

Direct antiviral agents

keyword
https://www.readbyqxmd.com/read/29145453/the-antiviral-drug-tenofovir-an-inhibitor-of-pannexin-1-mediated-atp-release-prevents-liver-and-skin-fibrosis-by-downregulating-adenosine-levels-in-the-liver-and-skin
#1
Jessica L Feig, Aranzazu Mediero, Carmen Corciulo, Hailing Liu, Jin Zhang, Miguel Perez-Aso, Laura Picard, Tuere Wilder, Bruce Cronstein
BACKGROUND: Fibrosing diseases are a leading cause of morbidity and mortality worldwide and, therefore, there is a need for safe and effective antifibrotic therapies. Adenosine, generated extracellularly by the dephosphorylation of adenine nucleotides, ligates specific receptors which play a critical role in development of hepatic and dermal fibrosis. Results of recent clinical trials indicate that tenofovir, a widely used antiviral agent, reverses hepatic fibrosis/cirrhosis in patients with chronic hepatitis B infection...
2017: PloS One
https://www.readbyqxmd.com/read/29145306/dynamic-noninvasive-markers-predict-hepatocellular-carcinoma-in-chronic-hepatitis-c-patients-without-sustained-virological-response-after-interferon-based-therapy-prioritize-who-needs-urgent-direct-acting-antiviral-agents
#2
Chao-Min Huang, Tsung-Hui Hu, Kuo-Chin Chang, Po-Lin Tseng, Sheng-Nan Lu, Chien-Hung Chen, Jing-Houng Wang, Chuan-Mo Lee, Ming-Chao Tsai, Ming-Tsung Lin, Yi-Hao Yen, Chao-Hung Hung, Chung-Lung Cho, Cheng-Kun Wu
Some patients with hepatitis C virus (HCV) infections who fail to achieve sustained virological responses (SVRs) after interferon (IFN) therapy do not develop hepatocellular carcinoma (HCC). Risk stratification of these patients may help identify those who would benefit most from treatment with direct-acting antivirals (DAAs).A total of 552 HCV-infected patients with non-SVR status were enrolled. Laboratory data before and after IFN treatment were analyzed to determine the relationship of changes in serum markers with development of HCC during the 7-year study period...
November 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29142128/interaction-between-a-unique-minor-protein-and-a-major-capsid-protein-of-bluetongue-virus-controls-virus-infectivity
#3
Eiko Matsuo, Kiyoshi Yamazaki, Hiroki Tsuruta, Polly Roy
Among the Reoviridae family of double-stranded RNA viruses, only members of the Orbivirus genus possess a unique structural protein, termed VP6, within their particles. Bluetongue virus (BTV), an important livestock pathogen, is the prototype Orbivirus The BTV VP6 is an ATP-dependent RNA helicase and it is indispensable for virus replication. In this report, we investigated how VP6 might be recruited to the virus capsid and whether the BTV structural protein VP3, which forms the internal layer of the virus capsid core, is involved in VP6 recruitment...
November 15, 2017: Journal of Virology
https://www.readbyqxmd.com/read/29139181/direct-antiviral-treatment-of-chronic-hepatitis-c-in-heart-transplant-recipients
#4
Martina Vitrone, Roberto Andini, Irene Mattucci, Ciro Maiello, Luigi Atripaldi, Emanuele Durante-Mangoni, Rosa Zampino
Direct-acting antiviral agents (DAAs) are a safe and effective treatment for chronic hepatitis C (CHC). This may be particularly valuable for patients with severe comorbidities or baseline conditions, including non-liver solid organ transplant. We report cases of two heart transplant recipients with CHC treated with DAA (sofosbuvir and daclatasvir) achieving sustained virological response. Treatment was well tolerated and no relevant side effects were observed. The drug-drug interactions and graft function were carefully monitored...
November 15, 2017: Transplant Infectious Disease: An Official Journal of the Transplantation Society
https://www.readbyqxmd.com/read/29137277/ningnanmycin-inhibits-tobacco-mosaic-virus-virulence-by-binding-directly-to-its-coat-protein-discs
#5
Xiangyang Li, Gefei Hao, Qingmin Wang, Zhuo Chen, Yan Ding, Lu Yu, Deyu Hu, Baoan Song
Tobacco mosaic virus (TMV) causes severe plant diseases worldwide; however, effective antiviral agents for controlling TMV infections are not available. This lack of effective antiviral agents is mainly due to the poor understanding of potential targets associated with TMV infections. During infection, the coat protein (CP), which is delivered by viral particles into susceptible host cells, provides protection for viral RNA. Here, we found that Ningnanmycin (NNM), a commercially used plant antibacterial agent, inhibits the assembly of the CP by directly binding several residues...
October 10, 2017: Oncotarget
https://www.readbyqxmd.com/read/29135030/hepatitis-c-virus-clearance-in-older-adults
#6
Antonio Massimo Ippolito, Angelo Iacobellis, Michele Milella, Fabio Conti, Vincenzo Messina, Maria Rosa Valvano, Grazia Anna Niro, Filomena Morisco, Michele Barone, Antonio Patrizio Termite, Giuseppina Brancaccio, Angelo Andriulli
OBJECTIVES: To determine whether older adults with the hepatitis C virus (HCV) achieve a sustained viral response (SVR) after treatment with direct-acting antiviral therapy. PARTICIPANTS: Individuals aged 80 and older with chronic HCV infection (N = 253; n = 213 with cirrhosis, n = 40 with advanced fibrosis). MEASUREMENTS: We investigated the efficacy, safety, and global clinical effect of treatment with different combinations of direct antiviral agents (DAAs)...
November 14, 2017: Journal of the American Geriatrics Society
https://www.readbyqxmd.com/read/29132303/prevalence-of-naturally-occurring-ns5a-resistance-associated-substitutions-in-patients-infected-with-hepatitis-c-virus-subtype-1a-1b-and-3a-co-infected-or-not-with-hiv-in-brazil
#7
Fernanda Malta, Karine Vieira Gaspareto, Gaspar Lisboa-Neto, Flair José Carrilho, Maria Cássia Mendes-Correa, João Renato Rebello Pinho
BACKGROUND: Non-structural 5A protein (NS5A) resistance-associated substitutions (RASs) have been identified in patients infected with hepatitis C virus (HCV), even prior to exposure to direct-acting antiviral agents (DAAs). Selection for these variants occurs rapidly during treatment and, in some cases, leads to antiviral treatment failure. DAAs are currently the standard of care for hepatitis C treatment in many parts of the world. Nevertheless, in Brazil, the prevalence of pre-existing NS5A RASs is largely unknown...
November 13, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/29125676/decreasing-mortality-and-disease-severity-in-hepatitis-c-patients-awaiting-liver-transplantation-in-the-united-states
#8
Allison Kwong, W Ray Kim, Ajitha Mannalithara, Nae-Yun Heo, Prowpanga Udompap, Donghee Kim
BACKGROUND: Hepatitis C virus (HCV) infection has been the leading indication for liver transplantation (LT) in the United States. Since 2013, interferon-free antiviral therapy has led to sustained virologic response in many LT candidates. We compared the waitlist mortality of HCV patients with that of patients with other chronic liver diseases. METHODS: Data for primary LT candidates were obtained from the Organ Procurement and Transplantation Network database...
November 10, 2017: Liver Transplantation
https://www.readbyqxmd.com/read/29123648/novel-therapeutic-approaches-to-simultaneously-target-rhinovirus-infection-and-asthma-copd-pathogenesis
#9
REVIEW
Carmen Mirabelli, Els Scheers, Johan Neyts
Rhinoviruses are exclusive respiratory pathogens and the etiological agents of the common cold. These viruses are increasingly reported to cause exacerbations of asthma and chronic obstructive pulmonary disease (COPD). Here, we review the role of rhinovirus infections in the pathogenesis of asthma and COPD and we discuss the current and potential future treatments. We propose that, in order to prevent exacerbations, the design of novel therapeutics should focus on directly acting antivirals but also include the design of drugs that simultaneously inhibit viral replication and alleviate symptoms of asthma and COPD...
2017: F1000Research
https://www.readbyqxmd.com/read/29118372/human-single-chain-transbodies-that-bound-to-domain-i-of-non-structural-protein-5a-ns5a-of-hepatitis-c-virus
#10
Kittirat Glab-Ampai, Monrat Chulanetra, Aijaz Ahmad Malik, Thanate Juntadech, Jeeraphong Thanongsaksrikul, Potjanee Srimanote, Kanyarat Thueng-In, Nitat Sookrung, Pongsri Tongtawe, Wanpen Chaicumpa
A safe and broadly effective direct acting anti-hepatitis C virus (HCV) agent that can withstand the viral mutation is needed. In this study, human single chain antibody variable fragments (HuscFvs) to conserved non-structural protein-5A (NS5A) of HCV were produced by phage display technology. Recombinant NS5A was used as bait for fishing-out the protein bound-phages from the HuscFv-phage display library. NS5A-bound HuscFvs produced by five phage transfected-E. coli clones were linked molecularly to nonaarginine (R9) for making them cell penetrable (become transbodies)...
November 8, 2017: Scientific Reports
https://www.readbyqxmd.com/read/29113004/direct-acting-antiviral-agents-in-the-treatment-of-chronic-hepatitis-c-real-life-experience-from-an-academic-centre-and-two-specialized-clinical-practices
#11
Manuel Jonathan Groß, Georg Härter, Johanna Backhus, Eugen Zizer, Thomas Seufferlein, Leopold Ludwig, Nektarios Dikopoulos
The introduction of the new direct antiviral agents has revolutionized the therapy of chronic hepatitis C. Today we are able to cure the vast majority of our patients with an 8- to 12-week therapy course of an antiviral combination therapy with an excellent safety profile. Real-life data are very important to further develop our experience with the new therapeutics and help us to improve the care of our patients in our everyday clinical practice.In our study, we present the retrospective analysis of a representative German cohort of 344 patients with chronic hepatitis C treated with the new direct antiviral agents...
November 7, 2017: Zeitschrift Für Gastroenterologie
https://www.readbyqxmd.com/read/29112331/intrapatient-viral-diversity-and-treatment-outcome-in-patients-with-genotype-3a-hepatitis-c-virus-infection-on-sofosbuvir-containing-regimens
#12
Neeru Bhardwaj, Manon Ragonnet-Cronin, Ben Murrell, Krishna Chodavarapu, Ross Martin, Silvia Chang, Michael D Miller, Jordan J Feld, Mark Sulkowski, Alessandra Mangia, Joel O Wertheim, Anu Osinusi, John McNally, Diana Brainard, Hongmei Mo, Evguenia S Svarovskaia
Treatment with the direct-acting antiviral agent (DAA) sofosbuvir (SOF), an NS5B inhibitor, and velpatasvir (VEL), an NS5A inhibitor, demonstrates viral cure rates of ≥95% in hepatitis C virus (HCV) genotypes (GT) 1-6. Here we investigated intrapatient HCV diversity in NS5A and NS5B using Shannon entropy to examine the relationship between viral diversity and treatment outcome. At baseline, HCV diversity was lowest in patients infected with HCV GT3 as compared to the other GTs, and viral diversity was greater in NS5A than NS5B (p<0...
November 7, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29111569/the-influence-of-immunosuppressants-on-direct-acting-antiviral-therapy-is-dependent-on-hepatitis-c-virus-genotype
#13
Alexandra Frey, Katja Piras-Straub, Andreas Walker, Jörg Timm, Guido Gerken, Kerstin Herzer
BACKGROUND: Direct-acting antivirals (DAA) have substantially increased sustained virological response rates after liver transplantation, with improved tolerance compared to interferon-based therapy. The influence of immunosuppressive agents on the efficacy of DAAs has not been clarified. METHODS: Subgenomic HCV replicons for genotype (GT) 1b, 2b, 3a and 4a were treated with the mammalian target of rapamycin (mTOR) inhibitors everolimus and sirolimus or with the calcineurin inhibitors (CNI) cyclosporine or tacrolimus, either alone or in combination with selected DAAs...
November 7, 2017: Transplant Infectious Disease: An Official Journal of the Transplantation Society
https://www.readbyqxmd.com/read/29108121/hepatitis-c-and-human-immunodeficiency-virus-co-infection-in-the-era-of-direct-acting-antiviral-agents-no-longer-a-difficult-to-treat-population
#14
Cameron Sikavi, Phillip H Chen, Alex D Lee, Elena G Saab, Gina Choi, Sammy Saab
BACKGROUND: The treatment of chronic hepatitis C (HCV) in human immunodeficiency virus 1 (HIV) infected individuals has been historically marked by low sustained virologic response (SVR) rates in comparison to those without HIV infection, resulting in the Food and Drug Administration (FDA) labeling those coinfected as a "special population with an unmet medical need." OBJECTIVES: We systematically reviewed the treatment of chronic HCV infection in those infected with HIV...
November 6, 2017: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/29106584/plasma-trough-concentrations-of-antiretrovirals-in-hiv-infected-persons-treated-with-direct-acting-antiviral-agents-for-hepatitis-c-in-the-real-world
#15
Massimo Tempestilli, Gabriele Fabbri, Ilaria Mastrorosa, Laura Timelli, Stefania Notari, Rita Bellagamba, Raffaella Libertone, Federico Lupi, Mauro Zaccarelli, Andrea Antinori, Chiara Agrati, Adriana Ammassari
Background: Possible drug-drug interactions (DDIs) between antiretrovirals (ARVs) and direct-acting antiviral agents (DAAs) are of some concern. Objectives: To investigate ARV plasma trough concentrations (Ctrough) before and during DAAs in patients treated in the real world. Methods: Single-centre, prospective, observational study including HIV/HCV coinfected persons undergoing DAA treatment. Self-reported adherence was assessed and ARVs Ctrough measured by HPLC-UV...
November 2, 2017: Journal of Antimicrobial Chemotherapy
https://www.readbyqxmd.com/read/29095723/antiviral-treatment-of-severe-non-influenza-respiratory-virus-infection
#16
Nathan J Brendish, Tristan W Clark
PURPOSE OF REVIEW: Non-influenza respiratory virus infections are a frequent cause of severe acute respiratory infections, especially in infants, the elderly, and the immunocompromised. We review here the current treatment options for non-influenza respiratory viruses and promising candidate antiviral agents currently in development. RECENT FINDINGS: Small molecule antiviral agents active against respiratory syncytial virus (RSV), such as ALS-8176 and GS-5806, show considerable promise in challenge studies and are undergoing late-phase clinical trials in hospitalised adults and children...
December 2017: Current Opinion in Infectious Diseases
https://www.readbyqxmd.com/read/29091196/efficacy-and-safety-of-direct-antiviral-agents-in-a-cohort-of-cirrhotic-hcv-hiv-coinfected-patients
#17
Jordi Navarro, Montserrat Laguno, Helem Haydee Vilchez, Jose M Guardiola, Jose A Carrion, Luis Force, Mireia Cairó, Carmen Cifuentes, Josep Vilaró, Josep Cucurull, Andrés Marco, Mercè Roget, Eva Erice, Manuel Crespo
Background: New direct-acting antiviral agents (DAAs) have shown great efficacy and tolerability in clinical trials and real-life cohorts. However, data are scarce regarding efficacy and safety in cirrhotic HCV/HIV-coinfected patients. Methods: A multicentre prospective analysis was performed in 13 Spanish hospitals, including all cirrhotic HCV/HIV-coinfected patients starting DAA combinations from January to December 2015. Sustained virological response 12 weeks after treatment (SVR12) was analysed...
October 1, 2017: Journal of Antimicrobial Chemotherapy
https://www.readbyqxmd.com/read/29084399/hepatitis-c-treatment-with-sofosbuvir-and-ledipasvir-accompanied-by-immediate-improvement-in-hemoglobin-a1c
#18
Atsuyuki Ikeda, Kaori Ikeda, Atsushi Takai, Ken Takahashi, Yoshihide Ueda, Hiroyuki Marusawa, Horoshi Seno, Nobuya Inagaki, Hiroyuki Kokuryu
BACKGROUND/AIMS: Direct-acting antiviral agents (DAAs) have increased the sustained viral response rate with minimal adverse effects and short treatment duration. In addition, recent data suggest the possibility that hepatitis C virus (HCV) clearance results in rapid improvement in metabolic pathways. The aim of the present study was to evaluate whether the DAA treatment without ribavirin lowers hemoglobin A1c (HbA1c) at 12 weeks after therapy completion. METHODS: We performed an observational study to assess the effect of sofosbuvir and ledipasvir (SOF/LED) treatment on glycemic control...
October 30, 2017: Digestion
https://www.readbyqxmd.com/read/29079285/a-novel-orally-available-small-molecule-that-inhibits-hepatitis-b-virus-expression
#19
Henrik Mueller, Steffen Wildum, Souphalone Luangsay, Johanna Walther, Anais Lopez, Philipp Tropberger, Giorgio Ottaviani, Wenzhe Lu, Neil John Parrott, Jitao David Zhang, Roland Schmucki, Tomas Racek, Jean-Christophe Hoflack, Erich Kueng, Floriane Point, Xue Zhou, Guido Steiner, Marc Lütgehetmann, Gianna Rapp, Tassilo Volz, Maura Dandri, Song Yang, John A T Young, Hassan Javanbakht
BACKGROUND & AIMS: The hallmarks of chronic HBV infection are a high viral load (HBV DNA) and even higher levels (>100-fold in excess of virions) of non-infectious membranous particles containing the tolerogenic viral S antigen (HBsAg). Currently, standard treatment effectively reduces viremia but only rarely results in a functional cure (defined as sustained HBsAg loss). There is an urgent need to identify novel therapies that reduce HBsAg levels and restore virus-specific immune responsiveness in patients...
October 24, 2017: Journal of Hepatology
https://www.readbyqxmd.com/read/29079161/hepatitis-c-virus-infection-in-the-older-patient
#20
REVIEW
Michael Reid, Jennifer C Price, Phyllis C Tien
Hepatitis C virus (HCV) is the most common blood-borne infection in the United States and is of concern in older adults. HCV infection is associated with not only hepatic but also extrahepatic comorbidities common to the aging patient including diabetes, kidney and cardiovascular diseases, and neurocognitive impairment. The effect of direct-acting antiviral agents to treat HCV on these outcomes is limited. This article summarizes the literature regarding the epidemiology and natural history of HCV infection; the impact of age on clinical outcomes in HCV-infected persons; and current knowledge regarding safety and efficacy of HCV treatment regimens in the older patient...
December 2017: Infectious Disease Clinics of North America
keyword
keyword
12534
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"